Roche acquires an interim injunction against Matrix Labs
The Madras High Court has in an ex parte order against Matrix Labs granted an interim injunction proscribing Matrix Labs from making and selling erlotinib hydrochloride. Matrix Labs had earlier filed a plea for revoking Roche’s patent with respect to the drug, which is useful for cancer treatment. The revocation plea is yet to be decided by the Appellate Board. The injunction has been granted for eight weeks. It is note worthy that the Delhi High Court had earlier rejected similar injunctions against generic companies.